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Abstract
Background: A large number of studies are attempting to identify alternative products from natural sources or
synthesized compounds that effectively interact with cancer cells without causing adverse effects on healthy cells.
Resorcinolic lipids are a class of bioactive compounds that possess anticancer activity and are able to interact with
the lipid bilayer. Therefore, the objective of this study was to synthesize a novel resorcinolic lipid and test its
biological proprieties.
Methods: We aimed to synthesize a novel resorcinolic lipid belonging to the class of cytosporones, AMS049 (3-Heptyl-
4,6-dihydroxy-3H-isobenzofuran-1-one) and to evaluate the toxicity of two concentrations of this lipid (7.5 and 10 mg/kg)
by determining its genotoxic, mutagenic, immunomodulatory, and apoptotic effects, as well as any biochemical and
histopathological alterations in mice treated with cyclophosphamide. The results were analyzed by ANOVA followed by
the Tukey test A . level of significance of p < 0.05 was adopted.
Results: The new cytosporone AMS049 was synthesized in only three steps and in satisfactory yields. The results indicate
that the compound is neither genotoxic nor mutagenic and does not alter biochemical parameters. The histological
alterations observed in the liver and kidneys did not compromise the function of these organs. Histology of the spleen
suggested immunomodulation, although no changes were observed in splenic phagocytosis or differential blood cell
count. The results also show that AMS049 potentiates the mutagenic effect of the chemotherapy drug
cyclophosphamide and that the combination induces apoptosis.
Conclusion: These facts indicate a potential therapeutic application of this novel cytosporone as an important
chemotherapeutic adjuvant.
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Background
A major difficulty in developing new drugs for the treat-
ment of cancer is the limited specificity of these com-
pounds, which often also affect non-tumor cells.
Therefore, a large number of studies are attempting to
identify alternative products from natural sources or
synthesized compounds that effectively interact with
cancer cells without causing adverse effects on healthy
cells [1] or that potentiate the effects of chemotherapy
drugs and reduce their side effects [2].
To evaluate new compounds, mutagenesis studies that
involve predictive testing for cancer combined with
immunomodulation and apoptosis assays are a good al-
ternative to outline and guide strategies for the preven-
tion and/or treatment of cancer [2, 3].
Phenolic lipids (especially resorcinolic lipids) are indi-
cated for the prevention and/or treatment of cancer. The
amphiphilic property of these compounds, which is attrib-
uted to the presence of non-isoprenoid side chains bound
to the hydroxybenzene ring, permits their interaction with
the lipid bilayer [4–6], the formation of liposomes [7], pro-
tection against oxidative stress [8] and the inhibition of
bacterial [9–11] and tumor cell growth [12, 13]. Par-
ticularly interesting are phenolic lipids of the cytospor-
one class, which present allelopathic activity [14] and
can interact with the orphan nuclear receptor Nur77,
triggering apoptosis [15]. This observation is supported
by a study from our research group showing that the
synthetic resorcinolic lipid 3-heptyl-3,4,6-trimethoxy-
3H-isobenzofuran-1-one (AMS35AA) has anti-genotoxic
and immunostimulatory activities, potentiates the muta-
genic effect of the chemotherapy drug cyclophospha-
mide and increases the rate of apoptosis induced by
this drug [2].
Continuing our studies on the synthesis and charac-
terization of new phenolic lipids and the evaluation of their
biological activities, the objectives of the present study
were to design and synthesize a novel cytosporone and to
evaluate its toxicity by determining its genotoxic, muta-
genic, immunomodulatory and apoptotic effects, as well as
any biochemical and histopathological alterations in Swiss
mice treated with cyclophosphamide.
Methods
Synthesis
Pro analysis (P.A.) grade solvents and reagents were pur-
chased from Acros® and Merck® and were purified, if ne-
cessary, following routine procedures.
Thin-layer chromatography (TLC) was performed on
silica gel 60 F254 (Merck®), and the chromatograms were
developed in a solution of vanillin in sulfuric acid,
followed by charring.
Compounds were purified by column chromatography
using silica gel (230 - 400 mesh ASTM) as the stationary
phase under pressure or by high-performance liquid chro-
matography (HPLC) on a Shimadzu® LC 6 AD chromato-
graph using a Shim-pack PREP-ODS (H) (260 × 20 mm)
column and UV-visible diode detector. The solvents were
evaporated in a Fisaton® 802D rotary evaporator.
The samples were weighed on an analytical balance
(Scientech®) with a precision ± 0.0001 g. The melting
point of the compounds was determined using a Quimis®
0340S23 melting point apparatus.
The nuclear magnetic resonance (NMR) spectra were
recorded on a Bruker Avance DPX-300 spectrometer at
frequencies of 300 and 75 MHz for the acquisition of
the 1H and 13C signals, respectively. The internal refer-
ence standard was adjusted from the TMS signal and
from residual signals of the solvents present in the deu-
terated solvent used to solubilize the sample (CDCl3 or
acetone-d6).
Mass spectra were obtained using an electron impact
mass spectrometer (70 eV) coupled to a gas chromato-
graph (Shimadzu®, CGMS QP2010 Plus). An RTx®-Wax
column from Restek® (crossbond, carbowax, polyethyl-
ene glycol; 30 m, 0.25 mm ID and 0.25 μm df) was used.
Helium gas was used as the mobile phase. The ultra-
high resolution and accuracy mass spectrometry (elec-
trospray ionization Fourier transform ion cyclotron
resonance mass spectrometry, ESI-FT-ICR MS, model
9.4 T Solarix, Bruker Daltonics, Bremen, Germany) was
used to define the elemental composition (CcHhNnOoSs),
DBE1 and m/z values over a mass range of m/z 200-
2000. A resolving power, m/Δm50% = 460 000, in which
Δm50% is the full peak width at half-maximum peak
height, of m/z ≅ 400 and a mass accuracy of < 2 ppm
provided the unambiguous molecular formula assign-
ments for singly charged molecular ions.
Phthalide 1 was prepared according to the procedures
described by Navarro et al. [2], in 93 % yield.
Synthesis of compound 2 (3-heptyl-4,6-dimethoxy-3H-
isobenzofuran-1-one)
Compound 1 (0.259 mmol, 76 mg) was solubilized in an-
hydrous ethanol (6 mL) and transferred to a sealed tube.
NaBH4 (1.293 mmol) was then added to the solution.
The system was completely sealed and stirred in an oil
bath at 120 °C for 12 hours. The tube was then cooled
to room temperature, and drops of glacial acetic acid
were added until the solution became transparent. The
solvent was distilled off, and the product was solubilized
in CH2Cl2, poured into a separatory funnel and washed
with NaCl dilluted solution twice. The organic phase
was then separated, dried over MgSO4 and filtered, and
the solvent was distilled under reduced pressure. The
product was purified by chromatography on a silica gel
column using a mixture of hexane:ethyl acetate (10:1, v/v)
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as the eluent, giving a white solid (p.f.: 80 - 81 °C) with
76 % yield.
1H NMR (CDCl3, 300 MHz). δ (ppm): 0.84 (t, J =
6.9 Hz, 3H); 1.22 (m, 10H); 1.61 (m, 1H); 2.16 (m, 1H);
3.82 (s, 3H); 3.83 (s, 3H); 5.41 (dd, J1 = 8.0 Hz and J2 =
2.9 Hz, 1H); 6.63 (d, J = 1.9 Hz, 1H); 6.87 (d, J = 1.9 Hz,
1H). 13C NMR (CDCl3, 75 MHz). δ (ppm): 14.1 (CH3)
22.6 (CH2); 24.7 (CH2); 29.1 (CH2); 29.3 (CH2); 31.7
(CH2); 32.9 (CH2); 55.6 (CH3); 55.9 (CH3); 80.8 (CH);
98.4 (CH); 104.8 (CH); 128.6 (C); 131.3 (C); 154.9 (C);
162.3 (C); 170.9 (C). IR (KBr tablet). νmax/cm
−1: 775,
860, 953, 1038, 1111, 1157, 1335, 1354, 1428, 1466,
1504, 1763, 2361, 2847, 2920, 3005. IE-MS fragments:
292 (M+.), 281, 253, 207, 193 (base peak), 165, 150, 135,
107, 77, 55.
Synthesis of compound 3 - cytosporone AMS049 (3-heptyl-
4,6-dihydroxy-3H-isobenzofuran-1-one)
Compound 2 (0.448 mmol, 130 mg) was solubilized in a
solution of 5 mL BBr3 in CH2Cl2 (1 M) into a two-neck
flask, which was completely closed and kept under mag-
netic agitation. After 2 hours, drops of a diluted solution
of HCl (5 mL) were added. The mixture was transferred
to a separatory funnel, and the organic phase (CH2Cl2)
was separated. The product was extracted from the
aqueous phase with CH2Cl2 (2 × 10 mL). The organic
phases were combined and washed with a diluted solu-
tion of Na2CO3 (1 × 5 mL). The resulting organic phase
was dried over MgSO4, filtered and concentrated. The
crude organic product was purified by chromatography
on a silica column (eluent 1/1, hexane:AcOEt, v/v), giv-
ing a white solid (83 % yield). 1H NMR (acetone-d6,
300 MHz). δ (ppm): 0.84 (t, J = 6.3 Hz, 3H); 1.25 - 1.31
(m, 10H); 1.66 - 1.73 (m, 1H); 2.20 - 2,24 (m, 1H); 5.43 -
5.46 (dd, J1 = 7.8 Hz, J2 = 3.0 Hz, 1H); 6.68 (d, J = 1.8 Hz,
1H); 6.72 (d, J = 1.8 Hz, 1H); 8.96 (sl, 1H); 9.28 (sl, 1H).
13C NMR (acetone-d6, 75 MHz). δ (ppm): 13.7 (CH3);
22.6 (CH2); 24.8 (CH2); 29.2 (CH2); 29.4 (CH2); 31.8
(CH2); 33.1 (CH2); 80.3 (CH); 101.8 (CH); 108.3 (CH);
128.2 (C); 129.1 (C); 153.3 (C); 160.1 (C); 170.4 (C). IR
(KBr tablet). νmax/cm
−1: 775, 868, 933, 1007, 1103, 1308,
1354, 1473, 1520, 1624, 1720, 2854, 2924, 2955, 3198.
IE-MS fragments: 264 (M+.), 253, 207, 191, 165 (base
peak), 137, 133, 109, 96, 73, 57, 45.
Chemical agents, animals, and experimental design
Cyclophosphamide (Fosfaseron®, Laboratórios Ítaca,
REG. M.S. No. 1.2603.0056.002-1; Batch 063020, Brazil),
an indirectly acting alkylating agent, was used as a posi-
tive control for the induction of DNA damage. The
DNA damage-inducing agent was prepared in saline,
pH 7.4, and administered intraperitoneally (ip) as a sin-
gle dose at a final concentration of 100 mg/kg body
weight (bw).
The cytosporone AMS049 was first diluted in ethanol
(1 %) and then in Milli-Q water (1 % final ethanol con-
centration) and administered at doses of 7.5 and 10 mg/kg
bw (ip) [16].
Sixty-five sexually mature, male Swiss mice (Mus mus-
culus) obtained from the Central Vivarium of the Center
for Biological and Health Sciences, Federal University of
Mato Grosso do Sul (Centro de Ciências Biológicas e da
Saúde, Universidade Federal de Mato Grosso do Sul -
CCBS/UFMS) were subdivided into two batches of 6
and 7 experimental groups (n = 5 animals). The first
batch was used for the peripheral blood micronucleus
test, splenic phagocytosis assay, differential blood cell
count, and histopathological analysis. The second batch
was used for the comet assay, biochemical analysis, and
apoptosis assay. The animals were housed in propylene
boxes covered with sawdust and were fed commercial
chow (Nuvital®) and filtered water ad libitum. The animals
were maintained at a controlled temperature (22 ± 2 °C)
and humidity (55 ± 10 %) on a ventilated cage rack
(Alesco®) with a photoperiod of 12 hours light/12 hours
dark. The experiment was conducted in accordance with
the guidelines of the Ethics Committee on the Use of Ani-
mals of Federal University of Mato Grosso do Sul (Proto-
col Nos. 399/2012 and 523/2013) and the Universal
Declaration of Animal Rights.
The following experimental groups were established:
Group 1 – Negative Control: The animals simultan-
eously received one dose of saline (cyclophosphamide ve-
hicle, ip) and one dose of saline plus 1 % ethanol (AMS049
vehicle, ip), each in a volume of 0.1 mL/10 g bw.
Group 2 – Positive Control – Cyclophosphamide: The
animals received one dose of cyclophosphamide
(100 mg/kg bw, ip) and one dose of saline plus 1 %
ethanol (AMS049 vehicle, ip) in a volume of 0.1 mL/
10 g bw.
Groups 3 and 4 – AMS049: The animals received one
dose of saline (cyclophosphamide vehicle, 0.1 mL/10 g
bw, ip) and one dose of AMS049 at the concentration of
7.5 (group 3) or 10 (group 4) mg/kg bw, ip.
Groups 5 and 6 – Combined: The animals simultan-
eously received one dose of AMS049 (at concentrations
of 7.5 (group 5) or 10 (group 6) mg/kg bw, ip) and one
dose of cyclophosphamide (100 mg/kg bw, ip).
Group 7 – Naive: The animals did not receive any type
of treatment. This group was used only in the second
batch of animals used for biochemical evaluation.
For animals in the first batch, peripheral blood samples
(20 μL) were collected for the micronucleus test at 24
(T1), 48 (T2), and 72 hours (T3) after administration of
the compounds. At T3, 20 μL peripheral blood was also
collected for differential blood cell analysis. Seventy-two
hours after application of the test compounds, the animals
were sacrificed by cervical dislocation for organ collection.
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The organs were weighed and used for histopathology and
evaluation of splenic phagocytosis. For animals in the sec-
ond batch, 20 μL peripheral blood was collected 24 hours
(T1) after administration of the test compounds for the
comet assay. After 72 hours, the animals were anesthe-
tized by intramuscular injection of 50 mg/kg ketamine
and 10 mg/kg xylazine, and blood was collected for the
biochemical assays by complete exsanguination through
the orbital plexus [17]. The animals were then euthanized




The comet assay was performed as described by Singh et
al. [18]. For this purpose, 20 μL peripheral blood and
120 μL low-melting point (LMP) agarose (0.5 %) were
homogenized. This solution was transferred to slides
previously coated with normal agarose (5 %), and the
biological material was covered with a glass coverslip.
The slides were cooled at 4 °C for 20 minutes. Next, the
coverslips were removed, and the slides were immersed
in freshly prepared lysis solution (89 mL stock lysis solu-
tion – 2.5 M NaCl; 100 mM EDTA; 10 mM Tris,
pH 10.0, adjusted with solid NaOH; 1.0 mL Triton X-
100; and 10.0 mL DMSO). Lysis was performed for
1 hour at 4 °C protected from light. The slides were then
transferred to an electrophoresis chamber containing
buffer with a pH > 13.0 (300 mM NaOH and 1 mM
EDTA, prepared from a stock solution of 10 N NaOH
and 200 mM EDTA, pH 10.0) for 20 minutes at 4 °C for
DNA denaturation. Electrophoresis was performed at
25 V and 300 mA (1.25 V/cm) for 20 minutes. After
electrophoresis, the slides were neutralized in 0.4 M
Tris-HCl (pH 7.5) for three cycles of 5 minutes each, air
dried and fixed in absolute ethyl alcohol for 10 minutes.
The material was stained with 100 μL ethidium bromide
(20 × 10−3 mg/mL) and analyzed under an epifluores-
cence microscope (Bioval®) at 40× magnification using a
420 - 490 nm excitation filter and a 520 nm barrier filter.
As described by Kobayashi et al. [19], 100 cells per ani-
mal were analyzed, and comets were classified as fol-
lows: (class 0) undamaged cells with no tail, (class 1)
cells with a tail smaller than the diameter of the nucleus,
(class 2) cells with a tail length one to two times the
diameter of the nucleus and (class 3) cells with a tail
length greater than two times the diameter of the nu-
cleus. Apoptotic cells containing a completely fragmen-
ted nucleus were not counted. The total score was
calculated from the sum of the values resulting from
multiplication of the total number of cells observed in
each damage class to which they belonged by the value
of the class.
Peripheral blood micronucleus test
The peripheral blood micronucleus test was performed
according to Hayashi et al. [20] and modified by Oliveira
et al. [21].
Apoptosis assay
One hundred microliters of a solution of macerated liver
or kidney was used for smear preparation. The slide was
fixed in Carnoy’s fixative for 5 minutes and subjected to
a decreasing ethanol series (95 % - 25 %). Next, the slide
was washed with McIlvaine buffer for 5 minutes, stained
with acridine orange (0.01 %, 5 minutes) and again
washed with buffer. Apoptotic cells were identified by
analyzing the DNA fragmentation patterns according to
Rovozzo and Burke [22] and Mauro et al. [23].
Splenic phagocytosis assay
The spleen was macerated in saline. One hundred microli-
ters of the cell suspension was transferred to a slide previ-
ously stained with 20 μL acridine orange (1.0 mg/mL) and
coverslipped. The slides were stored in a freezer until
analysis. The slides were analyzed under a fluorescence
microscope (Bioval®, Model L 2000A) at 400× magnifi-
cation using an excitation filter of 420 - 490 nm and a
barrier filter of 520 nm [24]. A total of 200 cells per
animal were analyzed. The absence or presence of
phagocytosis was defined based on the description of
Hayashi et al. [20].
Differential blood cell count
Twenty microliters of peripheral blood was used for
smear preparation on a histology slide. The slides were
air dried, stained with 10 % Giemsa for 10 minutes, and
examined by bright-field microscopy at 1000× magnifi-
cation. A total of 100 cells/animal were analyzed and dif-
ferentiated into lymphocytes, neutrophils, monocytes,
eosinophils and basophils.
Biochemical assays
After the collection and sedimentation of the blood sam-
ples in a refrigerator (4 °C), the serum was separated and
stored in a freezer (-10 °C) until analysis. The following
biochemical parameters were analyzed in an automated
Cobas 600 analyzer (Roche Diagnostics®) according to
manufacturer specifications: aspartate aminotransferase
(AST); alanine aminotransferase (ALT); urea; creatinine;
and Na+, K+, Ca2+ and Mg2+ ions.
Histopathological analysis
The liver, spleen, and kidneys were cut, and the frag-
ments were fixed in 10 % neutral buffered formalin and
submitted to routine processing for histological analysis.
Briefly, the fixed tissue fragments were dehydrated,
cleared, and embedded in paraffin. The samples were
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then cut into 6 μm-thick sections and stained with
hematoxylin-eosin for histopathological analysis.
Calculation of the percentage of damage reduction (%DR)
and damage increase (%DI)
Manoharan and Beneriee [25] and Waters [26] proposed
a calculation of the percentage of damage reduction to
evaluate the chemopreventive capacity of a substance
when it is combined with a known mutagenic agent. In
the present study, the test compound showed anti-
genotoxic but not antimutagenic activity. In the latter
case, an increase in the frequency of DNA damage was
observed. Therefore, in the present study, the percentage
of damage reduction and the percentage of damage in-
crease were calculated using the same formula.
DR%orDI% ¼ Mean of positive control–Mean of combination group
Mean ofpositive control–Mean ofnegative control
 100
Statistical analysis
The results are expressed as means ± standard errors
(SE) and were analyzed by ANOVA followed by the
Tukey test using the GraphPad Prism software (version
3.02; Graph-Pad Software, Inc., San Diego, CA, USA). A
level of significance of p < 0.05 was adopted.
Results
Planning and synthesis of the novel cytosporone
Figure 1 illustrates the retrosynthetic analysis of a new
cytosporone. The target compound is achieved by the key-
intermediate (phthalide 1) after hydrogenation followed by
demethylation reactions. Compound 1 was planned to be
obtained by the showed disconnection, leading to 3,5-
dimethoxybenzoic acid and octanoyl chloride as simpler
starting materials.
The designed synthetic cytosporone is structurally simi-
lar to cytosporones C and B isolated by Brady [27], espe-
cially in the presence of a lactone ring fused to the
aromatic ring. Cytosporone C is a δ-lactone resorcinol,
whereas the designed cytosporone and cytosporone E are
γ-lactones. However, the latter is hydroxylated at C-4.
The phthalide 1 was obtained as a product of the
Friedel-Crafts acylation of 3,5-dimethoxybenzoic acid
[2], which was treated with NaBH4 in ethanol at 120 °C
in a sealed tube. The workup was made after 12 hours,
and the compound was purified on a silica gel column
and analyzed by TLC and NMR spectroscopy, which re-
vealed the formation of only one product of interest
(compound 2) in 76 % yield after purification on a silica
gel column. Compound 2 was then treated with BBr3 in
dichloromethane at room temperature for 2 hours in
order to remove the methyl groups. This treatment pro-
vided the new cytosporone (compound 3), termed
AMS049, in 83 % yield (Fig. 2).
Compounds 2 and 3 were mainly identified based on
1H and 13C NMR spectral data.
The 1H NMR spectrum of compound 2 showed a
double doublet at 5.41 ppm, an important signal associ-
ated with the hydrogen of the stereogenic center formed
during reduction of the double bound of C-3. This re-
duction converts the second carbon of the lipophilic
chain, previously an sp2 hybridized carbon, into a dia-
stereotopic CH2 (C-10), which produces two multiplets
(1.58 - 1.65 and 2.15 - 2.29 ppm). In addition to the dis-
appearance of the signal for olefinic hydrogen above
6.00 ppm, the other signals were compatible with the
structure of compound 2. The 13C NMR spectrum, showed
a signal at 170.9 ppm that was assigned to the carbon of
the lactone carbonyl (C-1). The signal of the stereogenic
carbon (C-3) appeared at 80.8 ppm. These signals are in
accordande with heteronuclear single quantum coherence
Fig. 1 Retrosynthetic analysis of the novel cytosporone and structures of natural cytosporones C and E. FGI – Functional Group Interconversion
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spectroscopy (HSQC) and heteronuclear multiple-bond
correlation spectroscopy (HMBC) experiments, corrobor-
ating to characterize the structure of the product.
FTIR spectrum of compound 2 showed important bands,
such as that of the above alkyl C-H stretch slightly below
3,000 cm−1; stretching of the C-O bond of the carbonyl ester
at 1,763 cm−1; and C-H bond deformations in the aromatic
ring at 953, 860 and 775 cm−1, ameta-substitution pattern.
The 1H NMR spectrum of cytosporone 3 did not show the
signals corresponding to aromatic methoxyl groups above
3.50 ppm, but the presence of two large singlets at 8.96 and
9.28 ppm corresponding to phenolic hydrogens. The other
signals were the same as those observed in the 1H NMR
spectrum of precursor 2. Disappearance of the signals corre-
sponding to the carbons of the methoxyl groups was noted
in the 13C NMR spectrum, demonstrating the complete
deprotection of the product. Tables 1 and 2 show the 1H and
13C NMR spectral data for the non-isoprenoid lipids 2 and 3,
respectively (1H and 13C NMR spectra of compounds 2 and
3 are available in Additional files 1, 2, 3, 4 and 5).
Figure 3a-b show ESI-FT-ICR mass spectra for com-
pound 2 and 3, respectively. For compound 2, Fig. 3a,
ESI(+)-FT-ICR MS provides an unambiguous molecular
formula (M) of C17H24O4, where [M +Na]
+, [M + K]+,
[2 M +Na]+ and [2 M + K]+ ions with m/z of 315.1571,
331.1311, 607.3251 and 623.2991 are identified, respect-
ively. All present an accuracy mass < 2 ppm. The DBE =
6 for the [M +Na]+ and [M + K]+ ions allow indicating
the presence of an aromatic (DBE = 4) and one furan
(DBE = 1) rings, and one ketone group (DBE =1).
For compound 3, Fig. 3b, ESI(-)-FT-ICR MS provides
M of C15H20O4, where the [M - H]
−, [M + Cl]−, and
[2 M - H]− ions with m/z of 263.1289 (DBE = 6),
299.1056 (DBE =6) and 527.2648 (DBE = 11) are identi-
fied, respectively. All have an accuracy mass < 1 ppm.
Biological assays
No significant differences were observed in the initial
and final weight of the animals; weight gain; or absolute
Fig. 2 Synthesis of AMS049
Table 1 NMR data related to compounds 2 and 3
(1H at 300 MHz, CDCl3)
Hydrogen Compound
2a δ(ppm) (m/J Hz) 3b δ(ppm) (multiplicity/J Hz)
3 5,41 (dd/J1 = 8,0/J2 = 2,9) 5,45 (dd/J1 = 7,8/J2 = 3,0)
5 6,63 (d/1,9) 6,68 (d/1,8)
7 6,87 (d/1,9) 6,72 (d/1,8)
10 2,16 e 1,61 (m) 2,22 e 1,70 (m)
11 1,22 (m) 1,25-1,31 (m)
12 1,22 (m) 1,25-1,31 (m)
13 1,22 (m) 1,25-1,31 (m)
14 1,22 (m) 1,25-1,31 (m)
15 1,28 1,25-1,31 (m)
16 0,83 (t/J = 6,9) 0,84 (t/J = 6,3)
C-4-OCH3 3,82 (s) -
C-6-OCH3 3,83 (s) -
Ph-OH - 9,28 e 8,96 (sl)
aSolubilized in CDCl3.
bSolubilized in Acetone-d6
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and relative weight of the heart, liver, lungs and kidneys
(p > 0.05). Absolute and relative spleen weight was lower
in the groups treated with cyclophosphamide alone or in
combination with AMS049 (p < 0.05) (Fig. 4).
The cytosporone tested (AMS049) was not genotoxic
and exhibited discrete anti-genotoxic activity when admin-
istered in combination with cyclophosphamide (p > 0.05).
The %DRs were 33.02 and 33.33 % for the doses of 7.5 and
10 mg/kg, respectively (Table 3).
AMS049 exhibited no mutagenic activity at any dose
or time of evaluation. When compound 3 was adminis-
tered in combination with cyclophosphamide, increases
(p < 0.05) in the percentage of mutagenic damage by
38.88 and 35.35 % were observed at T1 with doses of 7.5
and 10 mg/kg, respectively. In contrast, the frequency of
micronuclei could not be determined at T2 and T3 because
of the small number of analyzable red blood cells (Table 4).
The administration of AMS049 resulted in 15.28- and
18.12-fold increases in the frequency of hepatic apop-
tosis at doses of 7.5 and 10 mg/kg, respectively, when
compared with the controls (p < 0.05). In the kidneys,
this frequency increased 15.20-fold and 15.51-fold at the
same doses. When cyclophosphamide was administered
alone, the frequency of apoptosis increased 21.08-fold in
the liver and 15.14-fold in the kidneys compared with
the controls (p < 0.05). In contrast, the combined ad-
ministration of cyclophosphamide and AMS049 at
doses of 7.5 and 10 mg/kg resulted in 1.68- and 1.74-
fold increases in the frequency of apoptosis in the liver
and 2.15- and 2.37-fold increases in the kidneys, re-
spectively, when compared with the cyclophosphamide
group (p < 0.05) (Table 5).
The administration of cyclophosphamide alone or in
combination with AMS049 reduced the number of cells
in the spleen (p < 0.05), demonstrating that phagocytosis
had occurred. In contrast, no changes were observed
when compound 3 was administered alone (Table 6).
The differential blood cell count indicated no differences
in the numbers of lymphocytes or basophils (p > 0.05),
which were within the reference range. In contrast, eosino-
phil counts were higher than the reference range, although
no significant differences were observed between groups.
Fig. 3 (a) ESI(+) and (b) ESI(-)FT-ICR mass spectra for compounds 2 and 3, respectively
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Despite the lack of significant differences in the number of
neutrophils (p > 0.05), groups 1, 2 and 5 presented higher
numbers than the reference ranges. An increase in the
number of monocytes was only observed in the group
treated with 10 mg/kg AMS049 (group 4) (p < 0.05). In
addition, monocyte counts higher than the reference range
were observed in this group and in group 5 (Table 7).
Analysis of biochemical profiles showed no alter-
ations in total glucose output (AST), dTDP-glucose
pyrophosphorylase (ALT), urea, creatinine, sodium,
potassium, calcium or magnesium (Table 8).
Histopathological analysis revealed normal liver morph-
ology in groups 1, 2, 3, and 4, in which the lobules were
filled with hepatocytes with preserved morphology, exhi-
biting the vascular portal triad in some areas. Cortical
glomeruli with preserved architecture were observed in
renal sections. The medullary renal tubules contained a
lightly eosinophilic material. In contrast, a reduction in
Bowman’s capsular space and congested blood vessels
were observed in the kidneys of animals treated with
cyclophosphamide in combination with AMS049. Histo-
logical sections of the liver showed cytoplasmic rarefaction
Fig. 4 Data of mice’ weights represented as graphic. a Initial, final and weight gain. b Absolute weight of the organs. c Relative weight of the
organs. Different letters indicate statistically significant differences (p < 0.05; ANOVA/Tukey test)
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and loss of cytoplasmic eosinophilia. Hyperplastic and re-
active lymphoid follicles, forming a germinal center, were
observed in splenic sections.
Discussion
A novel synthetic cytosporone was synthesized in only
three steps and with a satisfactory overall yield. The
cytosporone, called AMS049 in this study, was purified
and completely characterized using 1H and 13C NMR
spectroscopic techniques, and mass spectrometry
Studies suggest that cancer is caused by mutational
events [3] that induce the activation of proto-oncogenes
and the inactivation of tumor suppressor genes [28].
However, when mutations are induced in tumor cells by
chemotherapy drugs, apoptosis can also result. There-
fore, the mutational event is understood to be an im-
portant part of chemotherapy.
Within this context, there is a growing interest in
identifying anticancer substances [29] or compounds
that potentiate the effects of commercial chemotherapy
drugs [2] but without causing adverse effects on healthy
cells. In this respect, an interesting approach is to de-
sign, modify and synthesize organic compounds in the
laboratory to reduce these side effects, which was the
objective of the present study.
Several natural or synthetic resorcinolic lipids have
shown anticarcinogenic activity [1, 12, 13, 30–41], which
was also suggested by this study.
Toxicogenetic tests showed that AMS049 has no gen-
otoxic or mutagenic activity, suggesting that this com-
pound is nontoxic and is safe for use. This result is
supported by studies that demonstrated the absence of
toxicity of other phenolic lipids [2, 33–35, 41].
A chemopreventive potential of cytosporone was not
confirmed because the compound has no anti-genotoxic
activity and is able to potentiate the mutagenic effects of
the chemotherapy drug cyclophosphamide, suggesting
that the combined use of these compounds is correlated
with a larger number of mutational events that lead to
apoptosis.
Parikka [40] and Navarro [2] reported anti-genotoxic
activity for the phenolic lipids 5-n-alkylresorcinol (6 - 9)





Damage classes Score %DR
0 1 2 3
Group 1 22.80 ± 5.04a 77.40 ± 5.07 20.00 ± 4.86 2.80 ± 0.80 0.00 ± 0.00 25.60 ± 5.34a,b -
Group 2 86.40 ± 3.15c 13.20 ± 3.38 64.00 ± 2.02 17.20 ± 1.88 5.20 ± 1.39 114.00 ± 7.45c -
Group 3 30.80 ± 4.39a,b 69.20 ± 4.40 28.40 ± 3.96 2.40 ± 0.75 0.00 ± 0.00 33.20 ± 4.91a,b -
Group 4 48.80 ± 8.89b 51.20 ± 8.90 36.00 ± 4.61 12.40 ± 4.57 0.40 ± 0.40 62.00 ± 13.98b -
Group 5 65.40 ± 3.01b,c 34.60 ± 3.01 47.20 ± 2.59 13.80 ± 1.98 4.40 ± 1.57 88.00 ± 5.26b,c 33.02
Group 6 65.20 ± 5.81b,c 34.80 ± 5.81 50.20 ± 3.95 11.20 ± 3.93 3.80 ± 2.33 84.00 ± 13.52b.c 33.33
Group 7 NA NA NA NA NA NA NA
SE: Standard error
NA: Not analysed
%DR: Percentage of damage reduction
Different letters indicate statistically significant differences (p < 0.05; ANOVA/Tukey)
Table 4 Total frequency and mean ± SE of the micronucleus
assay in peripheral blood cells
Experimental
groups
Mean ± SE %DI
24 h (T1) 48 h (T2) 72 h (T3)
Group 1 8.80 ± 0.58ª 10.40 ± 2.31ª 13.20 ± 1.74ª -
Group 2 48.40 ± 1.21b 38.80 ± 2.96b 35.74 ± 1.79b -
Group 3 12.40 ± 2.29ª 7.40 ± 0.81ª 12.40 ± 1.50ª -
Group 4 9.20 ± 1.11ª 7.00 ± 0.89ª 14.00 ± 0.95ª -
Group 5 63.80 ± 6.89c NA NA 38.81
Group 6 62.40 ± 1.36c NA NA 35.35
Group 7 NA NA NA NA
SE: Standard error
NA: Not analysed
%DI: Percentage of damage increase
Different letters indicate statistically significant differences
(p < 0.05; ANOVA/Tukey)











Group 1 64 12.80 ± 2.40a 69 13.80 ± 1.88ª
Group 2 1349 269.80 ± 22.63b 1045 209.00 ± 42.42b
Group 3 978 195.60 ± 4.69b 1049 209.80 ± 8.63b
Group 4 1160 232.00 ± 20.38b 1070 214.00 ± 36.08b
Group 5 2272 454.40 ± 24.35c 2243 448.60 ± 24.92c
Group 6 2345 469.00 ± 38.45c 2480 496.00 ± 24.03c
Group 7 NA NA NA NA
SE: Standard error
NA: Not analyzed
Different letters indicate statistically significant differences
(p < 0.05; ANOVA/Tukey)
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and 3-heptyl-3,4,6-trimethoxy-3H-isobenzofuran-1-one
(4), respectively. If these compounds were used as chemo-
therapeutic adjuvants, the anti-genotoxic activity would not
be adequate or desired because it may impair apoptosis.
The lipophilicity (reported as Log P) of these com-
pounds and of other correlated substances is shown in
Table 9. Interestingly, in the series shown in this table,
the hydrophobicity of anti-genotoxic lipids 2, 4 and 6 -
10 was higher than 5, whereas that of compounds 1, 3
and cytosporone B (5) was lower than this value.
Cytosporone B is known to have anticancer activity
and acts as a natural physiological ligand for the orphan
nuclear receptor Nur77 in eukaryotic cells. The results
of molecular modeling were confirmed by the biological
responses obtained from in vivo tests in mice. Agonist
binding to the receptor leads to the activation of
receptor-related specific genes that control apoptosis
and metabolic regulation [41]. According to Liu [14],
the pharmacophoric components necessary for binding
to Nur77 include the hydroxybenzene ring and the
hydrophobic acyl chain, whereas the key element for
the activation of the biological function of Nur77 is an
ester group.
In contrast to compounds 4 and 6 - 9, the synthetic
cytosporone AMS049 designed and synthesized for this
study exhibits part of the features mentioned above, in-
cluding the presence of a phenol group as well as an
ester group (a five-membered lactone). This structure
does not contain the acyl group in the benzylic carbon
when compared to cytosporone B (Compound 5,
Table 9). However, this carbon is attached to an oxygen
atom, allowing interactions with biological receptors
through hydrogen bonding. Therefore, it is possible to
rationalize in a preliminary manner that the anticarcino-
genic activity of AMS049 is due to these structural char-
acteristics, which also confer moderate lipophilicity (Log
P 4.412), thus permitting balance between in vivo per-
meability and solubility.
The micronucleus test indicated that the simultan-
eous administration of AMS049 and cyclophosphamide
increased the frequency of DNA damage. This action
could be important for the treatment of cancer if cytos-
porone is used as an adjuvant because cyclophospha-
mide is cytotoxic to tumor cells by causing cellular
injury such as DNA damage, including micronuclei,
and by inducing a complex cascade of events that in-
volve the activation of caspases and cysteine proteases
[42]. A similar phenomenon was described by Navarro
[2], who evaluated the synthetic resorcinolic lipid
AMS35AA. However, the capacity of AMS049 to increase
DNA damage is greater, as indicated by the observation
that a lower dose (7.5 mg/kg) there was a DI% of 38.88 %.
This number is 2.01 times higher than that reported for
AMS35AA administered at a dose of 10 mg/kg.





Total of cells without phagocytosis evidence Total of cells with phagocytosis evidence
Absolute values Mean ± SE Percentage (%) Absolute values Mean ± SE Percentage (%)
Group 1 1000 241 48.20 ± 4.95ª 24.10 759 151,.80 ± 4.95ª 75.90
Group 2 1000 483 96.60 ± 1.85b 48.30 519 103.80 ± 1.88b 51.90
Group 3 1000 251 50.20 ± 4.15ª 25.10 749 149.80 ± 4.15ª 74.90
Group 4 1000 200 40.00 ± 4.78ª 20.00 800 160.00 ± 4.78ª 80.00
Group 5 1000 464 92.80 ± 2.01b 46.40 536 107.20 ± 2.01b 53.60
Group 6 1000 471 94.20 ± 2.58b 47.10 529 105.80 ± 2.57b 52.90
Group 7 NA NA NA NA NA NA NA
SE: Standard error
NA: Not analyzed
Different letters indicate statistically significant differences (p < 0.05; ANOVA/Tukey)




Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7
Lymphocyte 55 – 95 % 46.80 ± 1.96a,b 40.40 ± 3,21b 57.60 ± 1.20a 54.80 ± 1.42a 41.60 ± 3.58b 57.20 ± 4.81a NA
Neutrophil 10 – 40 % 48.80 ± 1.93a,b 55.20 ± 1,68b 35.40 ± 0.74a 37.40 ± 1.47a 52.60 ± 3.97b 37.60 ± 5.11a NA
Monocyte 0.1 – 3.5 % 2.20 ± 0.73b 2.40 ± 1.16a,b 3.20 ± 0.58a,b 5.80 ± 0.86a 3.80 ± 0.73a,b 3.20 ± 0.58a,b NA
Eosinophil 0 – 0.4 % 2.20 ± 0.58a 1.80 ± 0.58a 3.80 ± 0.58a 1.80 ± 0.58a 2.00 ± 0.54a 1.80 ± 0.58a NA
Basophil 0 – 0.3 % 0.00 ± 0.00a 0.20 ± 0.20a 0.00 ± 0.00a 0.20 ± 0.20a 0.00 ± 0.00a 0.20 ± 0.20a NA
SE: Standard error
Different letters indicate statistically significant differences (p < 0.05; ANOVA/Tukey)
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As observed by Navarro [2], in the present study, it
was not possible to quantify the frequency of micronu-
clei in erythrocytes of animals treated simultaneously
with cyclophosphamide and AMS049 after 24 hours.
This finding is likely due to the amphiphilic properties
of resorcinolic lipids. According to Kozubek and Tyman
[43], the stabilization of phenolic lipids and derivatives
in membranes is the result of the interaction of hydroxyl
groups of the aromatic ring with phospholipids via
hydrogen bonds. As a consequence, phenolic lipids are
rapidly and effectively incorporated into phospholipid
bilayers [44–46]. This occurrence may have increased
the permeability of the erythrocyte membrane to small
non-electrolytes with a molecular diameter of 1.4 nm
or less [47], as well as to water [5], causing lysis of the
cell [48, 49]. These factors, when combined with others
described in the literature such as the relationship be-
tween the hemolytic capacity of homologous resorcino-
lic lipids and the length and degree of unsaturation of
the aliphatic side chain [47], permit the inference that
AMS049 has high hemolytic activity. This explains the
absence of analyzable erythrocytes in the peripheral
blood micronucleus test.
The apoptosis assay demonstrated an increase in cell
death when AMS049 was administered alone or in
combination with cyclophosphamide. This observation
is important when considering the possible combined
application of this compound with a commercial
chemotherapy because an increase in cell damage can
trigger the death of tumor cells. In addition, chemo-
therapy increases the frequency of free radicals and re-
duces antioxidant defenses in the organism [50]. One
example is the reduction of superoxide dismutase [51],
which favors apoptosis of tumor cells or cells with gen-
etic instability when compared with normal cells.
Apoptosis is characterized by cell shrinkage, chro-
matin condensation, and the activation of specific
cysteine proteases, known as caspases [1]. Other
authors have demonstrated the apoptotic activity of
compounds similar to AMS049 [2, 14, 16, 41, 52–54],
suggesting the induction of apoptosis by the activation
of Nur77 [55, 56].
Nur77 is a unique transcription factor of the orphan
nuclear receptor superfamily [56]. The protein consists
of an amino-terminal transactivation domain, a DNA-
binding domain, and a carboxy-terminal ligand-binding
domain [57]. In cancer cells, Nur77 becomes a potent
activator of cell death in response to apoptotic stimuli
that induce its migration to the mitochondria. In mito-
chondria, Nur77 interacts with Bcl-2. This interaction
induces a conformational change of Bcl-2, triggering the
release of cytochrome c and, finally, apoptosis [58–60].
According to the literature, apoptosis triggered by
AMS049 analogs may occur through a cross-talk be-
tween Nur77 and BRE, a death receptor-associated
protein. This event is mediated specifically by repres-
sion of the transcriptional activity of BRE through re-
cruitment of the corepressor N-CoR, in which Nur77
binds to the BRE promoter, regulating the transcrip-
tion of this protein [61, 62].
Lin [58] suggested that AMS049 analogs such as
cytosporone B reduce the mitochondrial membrane
potential. In addition, critical events of apoptosis such
as the cleavage of caspase-9 and caspase-3 are induced
[14]. As discussed earlier, this is added to the activa-
tion of Nur77, which is possibly the result of the pres-
ence of an ester radical in the structure of these
compounds. Thus, because AMS049 is a lactone (cyc-
lic ester), it is possible to infer its capacity to activate
Nur77, triggering apoptosis. Taken together, these ob-
servations make resorcinolic lipids, including AMS049, an
interesting target for the development of new anticancer
therapies.
The results of the cell-based apoptosis assay were
corroborated by the histological findings, which
showed no change in the positive control group or the
Table 8 Biochemical evaluation of mice’ peripheral blood
Experimental
Groups
AST ALT Urea Creatinine Sodium Potassium Calcium Magnesium
(U/L) (U/L) (mg/dL) (mg/dL) (mEq/L) (mmol/L) (mg/dL) (mg/dL)
Group 1 114.2 ± 6.53a 59.4 ± 8.86a 64.30 ± 5.88a 0.28 ± 0.06a 125.0 ± 7.59a 67.4 ± 10.79a,b 9.86 ± 0.18a,b 0.38 ± 0.06a
Group 2 158.2 ± 8.32a,b,c 89.2 ± 12.74a 58.20 ± 4.62a 0.26 ± 0.02a 134.2 ± 1.93a 83.6 ± 4.41a 9.70 ± 0.21a,b 0.32 ± 0.02a
Group 3 146.8 ± 16.08a,b,c 101.4 ± 16.14a 61.62 ± 9.59a 0.30 ± 0.03a 136.2 ± 6.52a 35.8 ± 11.04b 8.98 ± 0.27b 0.44 ± 0.04a
Group 4 163.8 ± 14.39a,b,c 104.4 ± 21.48a 61.82 ± 5.43a 0.32 ± 0.04a 144.0 ± 7.43a 59.1 ± 16.13a,b 10.10 ± 0.14a 0.41 ± 0.05a
Group 5 183.4 ± 11.57b,c 102.4 ± 8.72a 48.22 ± 2.43a 0.40 ± 0.04a 134.2 ± 2.92a 50.6 ± 3.57a,b 9.78 ± 0.29a,b 0.40 ± 0.03a
Group 6 167.6 ± 14.91c 98.6 ± 29.56a 59.70 ± 2.79a 0.46 ± 0.13a 142.2 ± 1.59a 42.2 ± 10.38a,b 10.46 ± 0.10a 0.42 ± 0.03a
Group 7 118.0 ± 6.63a,c 63.2 ± 7.28a 57.00 ± 2.90a 0.28 ± 0.04a 122.8 ± 2.35a 50.8 ± 5.91ª,b 9.86 ± 0.09a,b 0.38 ± 0.05ª
SE: Standard error
AST - Aspartate aminotransferase
ALT - Alanine aminotransferase
Different letters indicate statistically significant differences (p < 0.05; ANOVA/Tukey)
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Table 9 Lipophilicity (Log P) related to some natural and synthetic phenolic lipids
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group treated with AMS049. In contrast, the livers of
animals treated with cyclophosphamide and AMS049
exhibited cytoplasmic rarefaction and eosinophilia,
findings characteristic of apoptotic events [63]. In
these cases, the cell-based assays showed high rates of
apoptotic cells. The high frequency of apoptosis also
observed in the kidneys might be related to blood ves-
sel congestion and a decrease in the filtration capacity
of this organ as demonstrated by the reduction in
Bowman’s capsular spaces.
Hyperplastic and reactive lymphoid follicles forming
a germinal center were observed in splenic tissue sec-
tions, a finding indicating immunomodulation. How-
ever, there was no significant change in the differential
blood cell count. In addition, a reduction in relative
spleen weight and in splenic phagocytosis levels was
observed in the groups treated with cyclophosphamide
alone or in combination with AMS049. These findings
are in contrast to what is expected because the increase in
circulating micronuclei should have increased splenic
phagocytosis. These data are still difficult to understand,
and further immunology studies are needed. However, a
similar situation has been reported in the literature. In a
study by Veiga [64], differential leukocyte counts in per-
ipheral blood remained unchanged in alcohol-treated ani-
mals even in the presence of marked lymphoid
hyperplasia in the spleen. Despite the difficulty in under-
standing these data, it is known that lymphocytic hypopla-
sia is associated with immunosuppressive factors and may
therefore be induced by the chemotherapy drug. Because
this did not occur, the immunomodulatory activity of
AMS049 in response to cyclophosphamide may indicate a
therapeutic potential that should be better evaluated.
Another type of immunostimulatory action was described
by Navarro [2] for AMS35AA when this compound was
administered simultaneously with cyclophosphamide, with
the authors observing a significant increase in the number
of lymphocytes.
Biochemical analysis revealed no alterations in AST,
ALT, urea, creatinine, sodium, potassium, calcium or
magnesium, indicating that the administration of the
resorcinolic lipid alone or in combination with cyclo-
phosphamide does not cause hepatic or renal damage.
These findings suggest that the histological alterations
observed in the liver and kidneys do not compromise
the function of these organs. These alterations may be
transient and could be regulated by apoptosis due to the
high frequency of this event in the two organs. The ab-
sence of toxicity and the safety of AMS049 are positives
for the biological effects of this lipid when compared
with AMS35AA because alterations in AST suggesting
hepatotoxicity have been described for the latter [2].
This gain suggests a beneficial effect and greater safety if
this lipid is indicated for therapeutic application.
Other studies also demonstrated that the incorporation
of this class of lipids into the membrane increases the effi-
cacy and reduces the side effects of chemotherapy drugs
because these drugs are transported and released by lipo-
somes whose formation is induced by the administration
of phenolic lipids [44, 65].
Conclusion
The present results permit the inference that AMS049
(compound 3) has therapeutic potential because it does
not cause genetic or biochemical changes under the experi-
mental conditions tested and tissue alterations appear to
be transient. In addition, the lipid potentiated the muta-
genic effect of cyclophosphamide, which may have resulted
in an increase in apoptosis. The immunomodulatory activ-
ity of AMS049 should also be highlighted. Taken together,
the results suggest that AMS049 can be indicated as an im-
portant chemotherapeutic adjuvant.
Table 9 Lipophilicity (Log P) related to some natural and synthetic phenolic lipids (Continued)
9 (C:21) 9.472
10 (C:23) 9.681
*The Theoretical Log P was calculated using the MolInspiration algorithm (http://www.molinspiration.com/cgi-bin/properties)
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Endnote
1DBE (double bond equivalent) = c – h/2 + n/2 + 1, where
c, h, and n are the number of carbon, hydrogen, and nitro-
gen atoms in the molecular formula, respectively.
Additional files
Additional file 1: Figure AF1. 1H NMR spectrum for compound
2 (300 MHz, CDCl3).
Additional file 2: Figure AF2. 13C NMR spectrum for compound
2 (75 MHz, CDCl3).
Additional file 3: Figure AF3. 1H NMR spectrum for compound
3 (300 MHz, Acetone-d6).
Additional file 4: Figure AF4. 13C NMR spectrum for compound
3 (75 MHz, Acetone-d6).




3-Heptyl-4,6-dihydroxy-3H-isobenzofuran-1-one; P.A.: Pro Analysis;
TMS: Tetramethylsilane; IR: Infrared; AcOEt: Ethyl acetate; EI-MS: Electron
impact mass spectrometry; AST: Aspartate aminotransferase; ALT: Alanine
aminotransferase; %DR: Percentage of damage reduction; %DI: Percentage of
damage increase; SE: Standard error of the average; LMP: Low melting point;
TLC: Thin layer chromatography; bw: Body weight; ip: Intraperitoneally;
HSQC: Heteronuclear single quantum coherence spectroscopy;
HMBC: Heteronuclear multiple-bond correlation spectroscopy; FTIR: Fourier
transform infrared spectroscopy; ESI-FT-ICR-MS: Electrospray ionization
Fourier transform ion cyclotron resonance mass spectrometry; HPLC: High-
performance liquid chromatography; FGI: Functional group interconversion.
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